Stock Events

Oxurion NV 

€0
44
+€0+0% Thursday 10:58

Statistics

Day High
0
Day Low
0
52W High
0.01
52W Low
0
Volume
264,116
Avg. Volume
8,955
Mkt Cap
678
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30SepExpected
Q4 2021
Q1 2022
Q3 2022
Q1 2023
Q3 2023
Q1 2024
Next
-0.18
-0.12
-0.06
0
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0G99.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap118.74B
Regeneron Pharmaceuticals competes in the ophthalmology space, particularly in treatments for eye diseases, similar to Oxurion's focus on diabetic eye disease treatments.
Novartis
NVS
Mkt Cap244.62B
Novartis offers a range of treatments for eye conditions, including macular degeneration and diabetic retinopathy, directly competing with Oxurion's product offerings.
Roche
RHHBY
Mkt Cap200.6B
Roche, through its Genentech division, develops therapies for ophthalmic diseases, competing in the same market as Oxurion, especially in the area of diabetic eye disease.
Bausch Health Companies
BHC
Mkt Cap2.68B
Bausch Health Companies, through its Bausch + Lomb segment, provides products for eye health, including treatments for retinal diseases, making it a competitor.
Abbvie
ABBV
Mkt Cap300.69B
AbbVie, having acquired Allergan, competes in the eye care market, particularly in treatments for retinal diseases, similar to Oxurion's focus.
Biogen
BIIB
Mkt Cap33.5B
Biogen has ventured into ophthalmology, including treatments for retinal diseases, positioning it as a competitor in the eye disease treatment market.
Nightstar Therapeutics
NITE
Mkt Cap19.65M
Nightstar Therapeutics, acquired by Biogen, focuses on gene therapies for inherited retinal disorders, competing in the advanced treatment segment of the market.
Adverum Biotechnologies
ADVM
Mkt Cap164.19M
Adverum Biotechnologies develops gene therapy products for eye diseases, including diabetic macular edema, making it a direct competitor in innovative treatments.

About

Oxurion NV, an integrated biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases and cancer in Belgium and internationally. Its lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687 an integrin antagonist that has completed Phase I clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, Parexel, INC Research, and Galapagos. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Show more...
CEO
Country
BE
ISIN
BE0003846632
WKN
000A0J30B

Listings